A Phase I/II, Multi-center, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma
Latest Information Update: 07 May 2024
At a glance
- Drugs ALMB-0168 (Primary)
- Indications Osteosarcoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors AlaMab Therapeutics
Most Recent Events
- 06 Jun 2023 Status changed from not yet recruiting to recruiting according to results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results (n=14) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 19 May 2021 New trial record